Hypertensive target organ damage predicts incident diabetes mellitus

European Heart Journal

Volumn 34, Issue 44, 2013, Pages 3419-3426

  Izzo, Raffaele ^a   De Simone, Giovanni ^a   Trimarco, Valentina ^b   Gerdts, Eva ^a,c,d   Giudice, Renata ^a   Vaccaro, Olga ^b   De Luca, Nicola ^a   Trimarco, Bruno ^b  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Diabetes; Hypertension; Metabolic syndrome; Target organ damage

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; THIAZIDE DIURETIC AGENT;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN;

DIABETES; HYPERTENSION; METABOLIC SYNDROME; TARGET ORGAN DAMAGE;

BODY MASS INDEX; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENTAL FINDINGS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84886278266     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht281     Document Type: Article

References (36)

1. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993;88(4 Pt 1):1444-1455.
2. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET,Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000;101:2271-2276.
3. GalderisiM, AndersonKM, WilsonPW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991;68:85-89.
4. Danaei G, LawesCM,VanderHoornS, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-Than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006;368: 1651-1659.
5. Stamler J, Vaccaro O, Neaton JD,Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
6. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T, BraunWald E, Jaffe AS, The MILIS Study Group. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989;14:49-57.
7. Izzo R, de Simone G, Chinali M, Iaccarino G, Trimarco V, Rozza F, Giudice R, Trimarco B, De Luca N. Insufficient control of blood pressure and incident diabetes. Diabetes Care 2009;32:845-850.
8. Gress TW, Nieto FJ, Shahar E,Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-912.
9. de Simone G, Devereux RB, RomanMJ, AldermanMH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 1994;23:600-606.
10. de Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A, KitzmanDW, Hopkins PN, Arnett DK, Devereux RB. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 2002;20:323-331.
11. Izzo R, de Simone G, Devereux RB, Giudice R, De Marco M, Cimmino CS, Vasta A, De Luca N, Trimarco B. Initial left-ventricular mass predicts probability of uncontrolled blood pressure in arterial hypertension. J Hypertens 2011;29:803-808.
12. De Luca N, Izzo R, Iaccarino G, Malini PL, Morisco C, Rozza F, Iovino GL, Rao MAE, Bodenizza C, Lanni F, Guerrera L, Arcucci O, Trimarco B. The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis. J Hypertens 2005;23:1417-1423.
13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
14. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004;43:1817-1822.
15. de Simone G, Olsen MH, Wachtell K, Hille DA, Dahlof B, Ibsen H, Kjeldsen SE, Lyle PA, Devereux RB. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens 2007;21:625-632.
16. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P,Waeber B, Williams B. 2007 Guidelines for the management of arterial hypertension: the Task Force for theManagement of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187.
17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, RomanMJ,Seward J, Shanewise JS, Solomon SD, SpencerKT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.
18. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ,CampoE, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-458.
19. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992;20:1251-1260.
20. Lembo G, De Luca N, Battagli C, Iovino G, Aretini A, Musicco M, Frati G, Pompeo F, Vecchione C, Trimarco B. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke 2001; 32:735-740.
21. de Simone G, Devereux RB, Roman MJ, Schlussel Y, Alderman MH, Laragh JH. Echocardiographic left ventricular mass and electrolyte intake predict arterial hypertension. Ann Intern Med 1991;114:202-209.
22. de Simone G, Devereux RB, Chinali M, Roman MJ,Welty TK, Lee ET, Howard BV. Left ventricular mass and incident hypertension in individuals with initial optimal blood pressure: the Strong Heart Study. J Hypertens 2008;26:1868-1874.
23. Grossman E, Shemesh J, Shamiss A, Thaler M, Carroll J, Rosenthal T. Left ventricular mass in diabetes-hypertension. Arch Intern Med 1992;152:1001-1004.
24. Wagenknecht LE, D'AgostinoRJr, Savage PJ, O'LearyDH,SaadMF, Haffner SM. Duration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997;28:999-1005.
25. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
26. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19:477-490.
27. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU. Endothelial dysfunction is detectable in young normotensive firstdegree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000;101:1780-1784.
28. Ferrannini E, Natali A. Insulin resistance and hypertension: connections with sodium metabolism. Am J Kidney Dis 1993;21(5 Suppl 2):37-42.
29. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-1214.
30. Howard BV, Best LG, Galloway JM, Howard WJ, Jones K, Lee ET, Ratner RE, Resnick HE, Devereux RB. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 2006;29:391-397.
31. Tooke JE. Microvascular function in human diabetes. A physiological perspective. Diabetes 1995;44:721-726.
32. Jaap AJ, Shore AC, Tooke JE. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia 1997;40:238-243.
33. Wong TY, Shankar A, Klein R, Klein BE, Hubbard LD. Retinal arteriolar narrowing, hypertension, and subsequent risk of diabetes mellitus. Arch Intern Med 2005;165: 1060-1065.
34. Tal MG. Type 2 diabetes: microvascular ischemia of pancreatic islets? Med Hypotheses 2009;73:357-358.
35. Fehsel K, Kolb-Bachofen V, Kroncke KD. Necrosis is the predominant type of islet cell death during development of insulin-dependent diabetes mellitus in BB rats. Lab Invest 2003;83:549-559.
36. Rothwell PM. External validity of randomised controlled trials: 'to whom do the results of this trial apply?' Lancet 2005;365:82-93.